SCHEMBL4375509

SCHEMBL4375509

CCCCOC(=O)c1ccc(NC(=S)NC(=O)COc2ccc(OC)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.67
ALDH1A1 P00352 8/20 0.67
SMN1; SMN2 Q16637 3/20 0.67
HPGD P15428 2/20 0.67
HTT P42858 2/20 0.67
KMT2A Q03164 3/20 0.59
POLB P06746 1/20 0.59
MAPK1 P28482 2/20 0.57
RECQL P46063 1/20 0.55
RNASEL Q05823 2/20 0.53
GAA P10253 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
KDM4E B2RXH2 1/20 0.52
MEN1 O00255 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4372355 0.92 MAPT (0.80) MAPTALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL4362279 0.92 MAPT (0.70) MAPTALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL4362068 0.91 MAPT (0.64) MAPTALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL14096046 0.91 ALDH1A1 (0.66) MAPTALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL4362148 0.91 MAPT (0.66) MAPTALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL4366220 0.89 MAPT (0.63) MAPTALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL4359859 0.88 HPGD (0.67) MAPTALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL4363264 0.87 ALDH1A1 (0.70) MAPTALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL14095985 0.87 KMT2A (0.64) MAPTALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL4366287 0.87 MAPT (0.64) MAPTALDH1A1SMN1; SMN2HPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7476686-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2009-01-13 US disclosed
US-7476686-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2009-01-13 US disclosed
US-7476686-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2009-01-13 US disclosed
US-7094807-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2006-08-22 US disclosed
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication CHEN DAWEI 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication NAT1, PIGS, SLC10A1 MAPT 3752/4885ALDH1A1 221/4885SMN1; SMN2 2335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.